key: cord-0897216-jrdlclru authors: Corcillo, Antonella; Whyte, Martin B; Vas, Prashanth; Karalliedde, Janaka title: Microvascular disease in diabetes and severe COVID-19 outcomes date: 2021-03-16 journal: Lancet Diabetes Endocrinol DOI: 10.1016/s2213-8587(21)00053-x sha: 8ebc0b2111599e00ca90bab89ddd8282e2a70f83 doc_id: 897216 cord_uid: jrdlclru nan Microvascular disease has been associated with worse outcomes in people with diabetes admitted to hospital for COVID-19. 2, 3 Pre-existing endothelial dysfunction and diffuse microangiopathy, particularly in the pulmonary microcirculation, may help to explain worse outcomes in people with diabetes. 3, 4 McGurnaghan and colleagues found a significantly higher risk of fatal or critical care unit-treated COVID-19 in people with diabetes and albuminuria, with an odds ratio of 1•352 (95% CI 1•155-1•583; p=0•0002) and 1•922 (1•519-2•430; p<0•0001) for microalbuminuria and macroalbuminuria compared with people with diabetes and normoalbuminuria. However, albuminuria status was unknown for 470 (43•4%) of 1082 people with fatal or critical care unit-treated COVID-19 and for 120 305 (37•8%) of 318 267 without fatal or critical care unit-treated COVID-19. These missing data might have affected why albuminuria, a biomarker of endothelial damage, was not selected in the final multivariable risk prediction model. Moreover, the strong biological association and probable statistical collinearity between microvascular complications and duration of diabetes could be another explanation why albuminuria and retinopathy were not included in the final risk prediction model. Whether imputation was used for albuminuria measurements or categories is unclear. Furthermore, it is not reported if there was any significant association observed between albuminuria results entered as a continuous variable and worse COVID-19 outcomes. The authors also observed that estimated glomerular filtration rate was significantly lower in people with fatal or critical care unit-treated COVID-19, even after adjustment for age and duration of diabetes. It would be valuable to know whether more advanced stages of chronic kidney disease were associated with worse outcomes, as observed in another study. 5 support, LMICs can harness national diabetes registry development to catalyse the development of systems for diabetes care. We declare no competing interests. type 1 diabetes, whereas type 2 diabetes accounts for 95% of global cases. 5 Some LMICs have hospital and localised registries, but the national registries that facilitate the wider benefits of understanding the prevalence and characteristics of diabetes in a country and intervention-targeting are scarce. National health information systems have been established and strengthened in many countries through global initiatives, improving collection and use of patient data for infectious diseases and maternal and child health programmes. Stronger data systems have been shown to improve the quality and continuity of patient care. 6 Programmes to strengthen health information systems aim to integrate electronic health records for case surveillance; to record, monitor, and follow-up patients across primary care and hospitals; and to direct data into aggregate electronic systems for routine disease surveillance systems. Conversely, inadequate health information systems have been identified as a reason for failure to translate national universal health coverage service packages for noncommunicable diseases (NCDs) into practice. 7 The next stage of data-driven health system strengthening therefore should be to ensure that diabetes (and other NCD) registries are prioritised and interoperable within frameworks for strengthening health information systems. This approach will lead to a more holistic understanding of patient needs and of national profiles of infectious diseases and NCDs and their interactions. Progressing from recommendation to development in practice in LMICs requires donors and governments to integrate registry establishment within strengthening programmes for national health information systems. Technical leadership beyond encouraging registry development is needed, including registry and system specifications and a curriculum on registry establishment, and the use of the registry to improve diagnosis and treatment. With this We read with great interest the Article by Stuart McGurnaghan and colleagues 1 on the cumulative risk of fatal or critical care unit-treated COVID-19 in people with diabetes compared with people without diabetes in Scotland. We would like to comment on and emphasise the importance of microvascular complications and indices of diabetic microangiopathy, such as retinopathy, albuminuria, and advanced diabetic kidney disease, as risk factors for more severe outcomes of COVID-19. As Corcillo and colleagues note, albuminuria was not selected in the prediction model. Missing values were imputed but, as Corcillo and colleagues also point out, collinearity with other variables can mean that strongly associated variables do not get selected. Because of the very strong association between albuminuria and reduced eGFR, and because eGFR was selected, the fact that albuminuria was not is unsurprising. As we note in our Article, "The variables retained in the model are those that are the most predictive and not necessarily causal". 1 HMC reports grants and personal fees from Eli Lilly and Novo Nordisk; grants from AstraZeneca, Regeneron, and Pfizer; institutional fees from Novartis and Sanofi Aventis; and being a shareholder with Roche Pharmaceuticals. All other authors declare no competing interests. We thank Antonella Corcillo and colleagues for their interest in our Article. 1 We fully agree with them on the importance of the association between microvascular disease and severe COVID-19 and its manifestation as associations with reduced estimated glomerular filtration rate (eGFR), albuminuria, and retinopathy. We also agree that the role of endothelial dysfunction in microvascular disease in diabetes suggests a common mechanism for the association with severe COVID-19. Indeed, in preliminary drafts from our Article we discussed this point, but space requirements meant that it was not included in the final version. Indeed, there is increasing recognition of the involvement of endothelial damage and microvascular dysfunction in COVID-19. 2 Endothelial dysfunction and microvascular disease are common in diabetes. 3 Albuminuria, reduced renal function, and retinopathy are all manifestations of endothelial damage and microvascular disease and all were associated with severe COVID-19 in our study. Regarding whether more advanced stages of chronic kidney disease were associated with worse COVID-19 outcomes, as observed in several studies, 4 we note that this association is reported in Supplementary Table 6 of the appendix of our Article where we show that an eGFR of less than 30 mL/min per 1•73 m² or being on renal replacement therapy was associated with a 2•37 times increased risk of severe COVID-19. 1 Pre-existing pulmonary endothelial dysfunction and microangiopathy can affect gas exchange. 4 Homoeostasis, through capillary recruitment, will then no longer be achieved in severe COVID-19, contributing to the severity of adult respiratory distress syndrome in patients with COVID-19. 6 Retinopathy or albuminuria may represent a burden of pre-existing pulmonary microangiopathy. Further research is needed to assess the role of microvascular disease in diabetes and severe COVID-19 outcomes. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study Diabetic retinopathy is independently associated with increased risk of intubation: a single centre cohort study of patients with diabetes hospitalised with COVID-19 The contribution of diabetic micro-angiopathy to adverse outcomes in COVID-19 Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study Inflammation and intussusceptive angiogenesis in COVID-19: everything in and out of flow We declare no competing interests.